Home › Onyx Snubbing Amgen Paves Way for 89% Deal Premium: Real M&A
 

Keywords :   


Onyx Snubbing Amgen Paves Way for 89% Deal Premium: Real M&A

2013-07-02 19:26:33| Chemicals - Topix.net

Onyx Pharmaceuticals Inc., which surged more than 50 percent after rejecting a bid from Amgen Inc., is betting that potential suitors from Bayer AG to Bristol-Myers Squibb Co.

Tags: real ma premium deal

Category:Chemicals

Latest from this category

All news
26.11ROSS VersaMix Multi Shaft Mixers are for Complex Formulations
26.11PPG Completes Sale of Silicas Products Business to QEMETICA
26.11¦nie¿ka Among Leaders of Sustainable Development in Poland
26.11Solvay Unveils Climate and Water Projects in Brazil with HRH Princess Astrid of Belgium
25.11PPG Recognized in Newsweeks Americas Greenest Companies List
25.11Axalta Wins Another Distinguished R&D 100 Award for Innovation
25.11Dunn-Edwards CEO Karl Altergott to Retire, COO Monte Lewis is Successor
25.11Global Market Insights: Auto Refinish Coating Market $17.79 Billion by 2032
Chemicals »
27.11JELEEBOX
27.11
27.11222CB
27.11BOSS ( ) BB-1X Bass Driver
27.1112010 re0827-141
27.11
27.11 2021 EDITION
27.11DVD
More »